Article
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.
Nature communications - 25 Sept 2024
Anastasiou Panayiotis, Moore Christopher, Rana Sareena, Tomaschko Mona, Pillsbury Claire E, de Castro Andrea, Boumelha Jesse, Mugarza Edurne, de Carné Trécesson Sophie, Mikolajczak Ania, Blaj Cristina, Goldstone Robert, Smith Jacqueline A M, Quintana Elsa, Molina-Arcas Miriam, Downward Julian
Abstract excerpt
Mutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but resistance develops rapidly. Here we use an inhibitor, (RMC-4998) that targets RASG12C in its active, GTP-bound form, to treat KRAS mutant lung cancer in various immune competent mouse models. RAS pathway reactivation after RMC-4998 treatment could be delayed using combined treatment with a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.